FCGR2A and neuroblastoma: We show that the efficacy of SUREK is highly dependent on the presence of FcγR+ antigen-presenting cells (APCs) in vitro supposing that SUREK-mediated cytotoxicity depends on the presence of tumor cells, T cells and APC in our syngeneic murine neuroblastoma model as well.